Drug
DRF
DRF is a pharmaceutical drug with 2 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
2
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(50%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
2
100%
Phase Distribution
0
Early Stage
2
Mid Stage
0
Late Stage
Phase Distribution2 total trials
Phase 2Efficacy & side effects
2(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
2
all time
Status Distribution
Active(1)
Completed(1)
Detailed Status
Completed1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
2
Active
1
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 22 (100.0%)
Trials by Status
completed150%
recruiting150%
Recent Activity
1 active trials
Showing 2 of 2
recruitingphase_2
DIROXIMEL FUMARATE TO REDUCE PERIHAEMATOMAL OEDEMA IN INTRACEREBRAL HAEMORRHAGE: DOUBLE BLIND RANDOMIZED CLINICAL TRIAL
NCT07275515
completedphase_2
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)
NCT05798520
Clinical Trials (2)
Showing 2 of 2 trials
NCT07275515Phase 2
DIROXIMEL FUMARATE TO REDUCE PERIHAEMATOMAL OEDEMA IN INTRACEREBRAL HAEMORRHAGE: DOUBLE BLIND RANDOMIZED CLINICAL TRIAL
NCT05798520Phase 2
A Study to Learn About the Safety of BIIB091 and Its Effect on Brain Inflammation When Taken Alone or With Diroximel Fumarate (DRF) in Adults With Relapsing Forms of Multiple Sclerosis (MS)
All 2 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 2